New GABA Modulator Promising in Depression
SAGE-217, a novel modulator of γ-aminobutyric acid–A (GABAA), reduced depressive symptoms in patients with major depression in a new study.Investigators compared patients who had major depression and were treated with SAGE-217 to patients who received placebo for a 2-week period. They found that a larger percentage of patients in the SAGE-217 group demonstrated a response to the treatment or remission, compared to those in the placebo group. There were no serious or severe adverse events. The study was published online Sep
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies